Bhutani D et al. Improvement in global longitudinal strain (GLS) correlates with NT-probnp response in patients with cardiac amyloidosis treated on a phase 1b study of anti-amyloid mab Cael-101. ASH 2018;Abstract 958.

Kastritis E et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021;385(1):46-58. Abstract

Khouri J et al. Safety, tolerability and efficacy of Cael-101 in AL amyloidosis patients treated on a phase 2, open-label, dose selection study to evaluate the safety and tolerability of Cael-101 in patients with AL amyloidosis. Blood 2020;136(1):21. Abstract

Palladini G et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: Safety run-in results of ANDROMEDA. Blood 2020;136(1):71-80. Abstract

Valent J et al. Myeloma/amyloidosis: Therapy, excluding transplantation; novel approaches for relapsed/refractory myeloma and amyloidosis. ASH 2021;Abstract 653.